logo

Rhythm Pharmaceuticals, Inc. (RYTM)



Trade RYTM now with
  Date
  Headline
9/20/2021 7:40:57 AM Rhythm Pharma Completes IMCIVREE SNDA Submission For Obesity & Control Of Hunger In Bardet-Biedl And Alström Syndromes
3/20/2021 11:34:49 AM Rhythm Pharmas Presents New Data From Phase 2 Basket Study In Patients With HET Obesity On Setmelanotide At ENDO 2021
1/5/2021 8:20:43 AM Rhythm Enters Definitive Agreement To Sell Its Rare Pediatric Disease PRV For $100 Mln
12/22/2020 7:05:43 AM Rhythm Pharma: Topline Results From Phase 3 Clinical Trial Of Setmelanotide In Bardet-Biedl Syndrome Meets Endpoints
11/27/2020 7:37:05 AM Rhythm Pharmaceuticals Says FDA Approved IMCIVREE For Chronic Weight Management
10/31/2020 10:04:07 AM Rhythm Announces Publication Of Results From Phase 3 Clinical Trials Of Setmelanotide In Lancet Diabetes & Endocrinology
7/20/2020 7:41:42 AM Rhythm Pharma Appoints David Meeker As CEO
7/1/2020 8:12:49 AM Rhythm Receives Rare Pediatric Disease Designation From FDA For Setmelanotide
3/30/2020 7:59:22 AM Rhythm Completes Rolling Submission Of NDA For Setmelanotide
3/18/2020 8:16:02 AM Rhythm Receives Orphan Drug Designation From FDA For Setmelanotide For Treatment Of Alström Syndrome